Australian (ASX) Stock Market Forum

ATH - Alterity Therapeutics

140120 - PBTs.gif
 
Hi,

Prana Commences US Investor Roadshow
Melbourne, Australia – Wednesday 22nd January, 2014; San Francisco, United States – Tuesday 21st January 2014: Prana Biotechnology (ASX:pBT/ NASDAQ:pRAN), a leading innovative drug developer targeting disease modification in neurodegenerative disease, is commencing a non-deal investor roadshow in the United States with Credit Suisse. The Corporate presentation includes: Information on the Company’s development programs and upcoming catalysts; Overview of the Huntington’s disease phase 2 clinical trial which is nearing the reporting of major clinical results; and Overview of the Alzheimer’s disease phase 2 clinical trial, which is expected to report in March 2014. Mr Geoffrey Kempler, President and Chief Executive Officer and Professor Rudy Tanzi, Prana’s Chief Scientific Advisor and Professor of Neurology, Harvard Medical School will be in attendance....

The rest of this announcement can be read by clicking on this link:-

http://stocknessmonster.com/news-item?S=PBT&E=ASX&N=401160

140122 - PBTs.gif
 
Hope non one here got caught in this train wreck, another speculative bio tech bites the dust. :(

http://www.bloomberg.com/news/2014-03-31/prana-biotech-plunges-76-drug-fails-in-alzheimer-study.html

I didn't get caught in the train wreck but feel sorry for those who were:(. I was working at Melbourne Uni in the early '90s when PBT started their research work, hoping to find a cure (or at least managing to slow it down) for AD/dementia - but unfortunatly it hasn't worked out that way. My Mom was admitted into an aged care facility (in Britain) 3 weeks ago after my Dad who had been looking after her over the past 18 months, could no longer as her Vascular dementia had reached a stage where she needed virtually 24 hours care.

Lets hope that someone else has better luck finding a cure for it


Regards
PB
 
Prana Biotechnology is making impressive gains today, days after announcing that Life Biosciences LLC is leading a strategic investment of up to A$44.5 million (US$31.4 million) in the company.

MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 28 December 2018: Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced that it has entered into a securities purchase agreement for a lead investment by Boston based Life Biosciences LLC (“Life Biosciences”) to raise up to approximately A$44.5 million (approx. US$31.4 million). Life Biosciences will initially invest US$7.5 million (approx. A$10.6 million), with the agreement allowing Prana to raise an additional US$2 million from other investors, totalling US$9.5 million (approx. A$13.4 million). A further amount of up to approximately A$31 million (approx. US$21.9 million) would be invested by Life Biosciences and other investors on exercise of short-term warrants being issued as part of the transaction.

https://iwatchmarkets.com/prana-biotechnology-pran-stock-flying-on-strategic-investment/1204/

PBT is currently up 60.63% to 5.3c so far today on volume of around 3 million shares.

big.chart-PBT.gif
 
On April 12th, 2019, Prana Biotechnology Limited (PBT) changed its name and ASX code to Alterity Therapeutics Limited (ATH).
 
Back and pumping again if anyone wants to watch the action:eek::roflmao:

Absolutely nuts!

Edit, it dropped around 700% whilst I was posting, and another 300 or so since...
not often that you get to see a stock jumping 30% or so each tick... craziness.
 
Last edited:
Has settled and been consolidating on or around 0.036 since the run mentioned above.
Hoping someone has done some due diligence FA and can ad any understanding to the mix?
Cheers
 
ATH has been up and down this year, but it's come roaring back to life today after announcing the allowance of a new composition of matter patent by the United States Patent and Trademark Office.

The patent is titled "Compounds for and Methods of Treating Diseases" and is "the product of in-house discovery research and is central to Alterity’s next generation drug development portfolio focussed on neurodegenerative diseases."

The news has seen the ATH share price surge 26.9% to 3.3c this morning where it is currently stuck due to the ASX's market data issues.

Looking into this one a bit closer to see if I can put this morning's announcement into context. Sounds very promising.
 
Go buy a chiko roll and wait for the train when it comes back in.
I see you know my weak points,...
After a day in Luxembourg, I ended up travelling to Belgium instead of back to Strasbourg.... all because of a Baguette and some "foreign interference"... long story.

By memory Greggles, the Bank of NY mellonheads own a decent chunk of this one.
 
By memory Greggles, the Bank of NY mellonheads own a decent chunk of this one.

Interesting.

But biotech stocks scare me. Holding them is like defusing a bomb. You never know if or when it is going to go off and blow you up. You can do very well out of them, but you can very easily go to $0 as well.

I would trade them, but would avoid holding them long term unless I really understood the business and the therapy or treatment they were working on.

I'll have a look at this one to see if I can understand it a little better.
 
It is still down today @ 0.031

Back up again today after announcing that it is the recipient of funding from the Michael J. Fox foundation for Parkinson's Research.

ATH090221.png


Currently trading at 4.7c (up 20.5%) but hit an intraday high of 5.3c.

Parkinson's is a big deal. It remains uncured and according to Wikipedia, "In 2015, PD affected 6.2 million people and resulted in about 117,400 deaths globally".

So a big market for any successful treatment.

Even though I'm not into biotechs this one is probably worth keeping an eye on.
 
best close since nov 20
opened .034, low .033 (low volume) then steady rise into the close
not a lot to see in the chart, yet the steady rise and price not getting treated as a liquidity binge suggests more upside

"....that ATH434 preserves neurons while reducingα-synucleinin areas of pathology is exactly
what we were hoping to see as we advance to clinical trials in MSA,” said Alterity Chief Executive Officer David Stamler, M.D. "
 
Top